Soft tissue augmentation using sculptra

Facial Plastic Surgery

Volumn 20, Issue 2, 2004, Pages 157-163

  Humble, Gail ^a,b   Wiest, Douglas ^b  

^a Blue Pacific Aesthetic Medical Group   (United States)

^b Blue Pacific Aesthetic Medical Group   (United States)

Author keywords

Facial fat loss; Lipoatrophy; Poly L lactic acid; Sculptra; Volume replacement

Indexed keywords

FILLER; POLYLACTIC ACID;

EDEMA; ERYTHEMA; HEMATOMA; HUMAN; IMPLANT; INFLAMMATION; NONHUMAN; REVIEW; SOFT TISSUE;

BIOCOMPATIBLE MATERIALS; COLLAGEN; HUMANS; LACTIC ACID; LIPODYSTROPHY; MICROSPHERES; POLYMERS; PROSTHESES AND IMPLANTS; RHYTIDOPLASTY;

EID: 11344258941     PISSN: 07366825     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-861758     Document Type: Review

References (11)

1. Brady JM, Cutright DE, Miller RA, Barristone GC. Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J Biomed Mater Res 1973;7:155-166
2. Cutright DE, Perez B, Beasley JD III, Larson WJ, Posey WR. Degradation rates of polymers and copolymers of polylactic and polyglycolic acids. Oral Surg Oral Med Oral Pathol 1974;37:142-152
3. Sattler G. Long-lasting results with polylactic acid. Derm 2003;9:422-423
4. Amard & Saint Marc Polylactic acid in the treatment of HIV-associated lipoatrophy. Second Lipodystrophy Workshop, Toronto, Canada; September 2000
5. Mest DM, Humble G. Hermosa Beach, California, Current IDE#G020113
6. Lafaurie M. Dolivio, St. Louis Hospital, Paris, France. Treatment of lipoatrophy with injections of polylactic acid. Tenth Conference for Retrovirus and Opportunistic Infection February 2003
7. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004;5:82-87
8. Mest D, Humble G. Safety and efficiency of intradermal poly-L-lactic acid (Sculptura) injections for patients with HIV associated facial lipoatrophy. Antivir Ther 2004;9:L36
9. Engelhard P, Knies M. Safety and efficacy of New-Fill® (polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF). XIV International AIDS Conference. Barcelona, Spain; July 7-12, 2002
10. Sommer B. Crystalline polyactic acid (New-Fill): current handling guidelines. Skin; 2004;15
11. Vleggaar D, Bauer U. Facial enhancement and the European experience with poly-L-lactic acid. J Drugs Dermatol 2004;3:542-547